Extracellular Vesicles as Future Therapeutics and Indicators of Cardiac Disease
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 2922
Special Issue Editors
Interests: ischemic heart disease; myocardial infarction; cardiac regeneration; extracellular vesicles; exosomes; modified mRNA
Interests: myocardial infarction; extracellular vesicles; stem cell biology; cardiovascular diseases; translational medicine
Special Issue Information
Dear Colleagues,
Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity worldwide. Although extensive research and studies have been carried out to improve the treatment and prognosis of CVDs, current treatment and diagnostic strategies are not satisfying. Extracellular vesicles have attracted significant attention in mediating intercellular communication during cardiovascular development and pathophysiology. Exosomal ncRNAs, including microRNAs, lncRNAs, and circRNAs, are considered to be key players, offering a potential source of novel diagnostic and prognostic biomarkers for CVDs. Stem-cell-derived exosomes can be used as a novel alternative to cell therapies in cardiovascular disease owing to their biocompatibility and non-immunogenicity. However, hurdles regarding exosome purification, batch difference, dosage, and untargeted delivery need to be overcome in preclinical and clinical practice.
This Special Issue aims to highlight the novel studies and strategies that might overcome current obstacles in cardiovascular translational medicine and their potential applications. Original research and review articles are welcome.
Specific themes we would like contributors to address include, but are not limited to:
- Extracellular vesicles in cardiac cells differentiation;
- Extracellular vesicles in cardiovascular repair and regeneration;
- Extracellular vesicles in cardiovascular protection;
- Extracellular vesicles in cardiovascular drug development and safety assay;
- Extracellular vesicles in tissue engineering;
- Extracellular vesicles in CVD diagnostic and prognostic;
- Extracellular vesicles in CVD pathogenesis;
- Extracellular vesicles in cardiovascular homeostasis.
Dr. Jiacheng Sun
Dr. Junjie Yang
Dr. Yu-An Lu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cardiovascular disease
- ncRNA
- extracellular vesicles
- cardiac regeneration
- diagnostics
- therapeutics
